Frenxit® Tablet: Each film coated tablet contains Flupentixol Dihydrochloride BP equivalent to 0.5 mg Flupentixol and Melitracen Hydrochloride INN equivalent to 10 mg Melitracen.
Frenxit is a preparation of Flupentixol and Melitracen. Flupentixol is a neuroleptic with anxiolytic and antidepressant properties when given in small doses, and Melitracen is a bipolar thymoleptic with activating properties in low doses. In combination the compound renders a preparation with antidepressant, anxiolytic and activating properties.
Adults: Usually 2 tablets daily (morning and noon). In severe cases the morning dose may be increased to 2 tablets. Elderly patients: 1 tablet in the morning.
Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Second dose should not be taken after 4 pm.
Flupentixol and Melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO inhibitors may cause hypertensive crisis. Neuroleptics and thymoleptics reduce the antihypertensive effect of Guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.
In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
Flupentixol and Melitracen should preferably not be given during pregnancy and lactation.
If previously the patient has been treated with tranquilizers with sedative effects these should be withdrawn gradually.
190.
THERAPEUTIC INDEX